Magnesium Sulfate Aurum Pharmaceuticals (Magnesium Sulfate Heptahydrate)

Magnesium sulfate supplies Mg2+ ions that act as calcium antagonists, stabilising neuronal membranes, reducing acetylcholine release at neuromuscular junctions, and relaxing smooth muscle. These actions lower excitability, help control seizures, correct cardiac rhythm disturbances, and inhibit uterine contractions, thereby addressing the underlying pathophysiology of its approved uses.

The specific dose and infusion rate of magnesium sulfate are determined by the prescribing clinician based on the indication, patient weight, renal function, and clinical response. Healthcare professionals calculate the appropriate regimen and monitor serum magnesium levels to ensure safe and effective therapy.

Magnesium sulfate is classified as pregnancy category unknown, but it is commonly used in obstetric care for eclampsia, pre‑eclampsia, and preterm labor when the benefits outweigh potential risks. Limited data exist on excretion into breast milk; clinicians should evaluate the risk‑benefit profile for nursing mothers on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Magnesium sulfate is the preferred source of magnesium for rapid intravenous or intramuscular repletion, whereas other electrolytes such as potassium chloride or calcium gluconate address different deficiencies. Compared with oral magnesium salts, the injectable form achieves faster serum level correction and is essential in acute settings like eclampsia or severe arrhythmias.

Magnesium Sulfate Aurum Pharmaceuticals should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the vial. Before use, inspect for particulate matter or discoloration and discard if the solution appears compromised.

The product is supplied as a sterile injectable solution for intramuscular or intravenous administration. Intravenous infusion should be performed slowly, often using a controlled infusion pump, while intramuscular injection is given into a large muscle group. Administration technique follows institutional protocols and the prescriber's instructions.

Serious risks include hypermagnesemia, which can cause muscle weakness, respiratory depression, hypotension, cardiac arrhythmias, and cardiac arrest. Rapid intravenous administration may also precipitate sudden drops in blood pressure. Prompt monitoring of serum magnesium, blood pressure, and respiratory status is essential to mitigate these hazards.

Magnesium sulfate is contraindicated in patients with known hypersensitivity to magnesium salts, severe renal failure where clearance is markedly reduced, and in individuals with existing profound hypotension or heart block unless closely monitored. Clinicians must assess each patient’s medical history before initiating therapy.